Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?

Gianluca Trifirò (), Salvatore Crisafulli, Giuseppe Andò, Giorgio Racagni and Filippo Drago
Additional contact information
Gianluca Trifirò: University of Messina
Salvatore Crisafulli: University of Messina
Giuseppe Andò: University of Messina
Giorgio Racagni: University of Milan
Filippo Drago: University of Catania

Drug Safety, 2020, vol. 43, issue 6, No 1, 507-509

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00935-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:6:d:10.1007_s40264-020-00935-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00935-2

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().